Personalized Gene Therapy Treatment Market Future Outlook Showing Growth Toward $7.83 Billion By 2030
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Large Will The Personalized Gene Therapy Treatment Market Be By 2030 Compared To Its 2026 Market Size?
The personalized gene therapy treatment market has seen its size expand rapidly in recent years. It is anticipated to grow from $8.38 billion in 2025 to $10.11 billion in 2026, registering a compound annual growth rate (CAGR) of 20.7%. This expansion during the historical period is primarily due to the increasing prevalence of genetic disorders, advancements in genomic sequencing technologies, early clinical success of targeted gene therapies, expansion of specialized gene therapy research centers, and increasing investment in precision medicine.
The personalized gene therapy treatment market is anticipated to experience substantial growth over the coming years. This market is projected to reach $21.23 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.4%. Factors contributing to this growth during the forecast period include a rise in regulatory approvals for personalized gene therapies, an escalating demand for tailored oncology treatments, the expansion of gene therapy manufacturing capacities, the increasing incorporation of AI in therapy design, and the wider adoption of pharmacogenomics-guided treatments. Key trends expected over the forecast period encompass a greater uptake of gene editing-based therapies, the increasing utilization of personalized treatment protocols, the expanding integration of companion diagnostics, the enlargement of both viral and non-viral vector platforms, and a heightened emphasis on precision oncology applications.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28293&type=smp
Which Key Drivers Are Affecting The Personalized Gene Therapy Treatment Market Development?
The rising incidence of genetic disorders is projected to fuel the expansion of the personalized gene therapy treatment market in the coming years. Genetic disorders are conditions that arise from DNA abnormalities, leading to disruptions in normal bodily functions. The increasing prevalence of these disorders is partly attributable to rising parental age, as older reproductive cells are more susceptible to mutations that can be passed to offspring. Personalized gene therapy offers a solution by precisely correcting the defective genes responsible for these conditions, tailoring treatments to an individual’s genetic makeup to enhance effectiveness and minimize side effects. For instance, according to information released in October 2024 by the Cystic Fibrosis Trust, a UK-based charity dedicated to supporting individuals with cystic fibrosis, approximately 11,148 cystic fibrosis (a genetic disorder) patients were registered in 2022, a number that subsequently rose to 11,318 in 2023, indicating a 1.5% year-over-year increase in patient registrations. Hence, the escalating occurrence of genetic disorders is significantly driving the growth of the personalized gene therapy treatment market.
Which Segment Classifications Are Used In The Personalized Gene Therapy Treatment Market Segment Analysis?
The personalized gene therapy treatment market covered in this report is segmented –
1) By Therapy: Targeted Treatments, Pharmacogenomics
2) By Vector Type: Viral, Non-Viral
3) By Distribution Channel: Hospitals, Clinics, Home Administration, Other Distribution Channels
4) By Application: Oncology, Neurology, Hematological, Infectious Diseases, Ophthalmology, Other Applications
Subsegments:
1) By Targeted Treatments: Monoclonal Antibodies, Chimeric Antigen Receptor T-Cell Therapy (CAR-T), Small Interfering RNA (siRNA) Therapy, Antisense Oligonucleotides (ASO), Gene Editing Therapy
2) By Pharmacogenomics: Companion Diagnostics, Drug Metabolism Enzyme Testing, Genetic Biomarker Analysis, Single Nucleotide Polymorphism (SNP) Profiling, Adverse Drug Reaction (ADR) Prediction
Which Trends Are Contributing To Changes In The Personalized Gene Therapy Treatment Market?
Major companies operating in the personalized gene therapy treatment market are actively pursuing strategic partnerships to enhance their technological capabilities and provide innovative therapies to patients more efficiently. These collaborative alliances allow organizations to leverage each other’s strengths and resources for mutual growth and competitive advantage, while simultaneously sharing risks and benefits. For instance, in May 2025, Aldevron, a US-based company involved in the production of DNA, RNA, and protein, collaborated with Integrated DNA Technologies, a US-based provider of genomics solutions, to manufacture the world’s first mRNA-based personalized CRISPR therapy. This therapy was developed to treat an infant suffering from urea cycle disorder (UCD), a rare and life-threatening genetic condition. Notably, this N of 1 therapy was developed and delivered in just six months, incorporating a custom guide RNA, an mRNA-encoded base editor, off-target safety services, and a clinically validated lipid nanoparticle delivery system. The development of this treatment marks a significant milestone in personalized *in vivo* base-editing therapies.
Which Firms Are Contributing To The Personalized Gene Therapy Treatment Market Ecosystem?
Major companies operating in the personalized gene therapy treatment market are Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc., Helix OpCo LLC, Personalis Inc., Dante Genomics, Gene By Gene Ltd., Veritas Genetics Inc., Futura Genetics, Nebula Genomics Inc., Pathway Genomics Corporation
Get The Full Personalized Gene Therapy Treatment Market Report:
Which Region Accounts For The Largest Portion Of The Personalized Gene Therapy Treatment Market?
North America was the largest region in the personalized gene therapy treatment market in 2025. The regions covered in the personalized gene therapy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Personalized Gene Therapy Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Personalized Gene Therapy Treatment Market 2026, By The Business Research Company
Genes Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Nucleic Acid Based Gene Therapy Market Report 2026
Cell And Gene Therapy Clinical Trial Services Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
